Astria Therapeutics, Inc. (ATXS)
Jan 26, 2026 - ATXS was delisted (reason: acquired by BCRX)
12.58
0.00 (0.00%)
Inactive · Last trade price on Jan 22, 2026
Astria Therapeutics Revenue
Astria Therapeutics had revenue of $706.00K in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $706.00K.
Revenue (ttm)
$706.00K
Revenue Growth
n/a
P/S Ratio
1,017.18
Revenue / Employee
$9,051
Employees
78
Market Cap
718.13M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionATXS News
- 6 days ago - Astria Stockholders Vote to Approve Acquisition by BioCryst - Business Wire
- 2 months ago - Astria Therapeutics: Updating Target Price, Biocryst Deal Expected To Go Through, Hold - Seeking Alpha
- 2 months ago - Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update - Business Wire
- 2 months ago - Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart - Business Wire
- 3 months ago - Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting - Business Wire
- 3 months ago - Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS - Business Wire
- 3 months ago - BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate' - Benzinga
- 3 months ago - BioCryst to buy Astria Therapeutics in $700 million deal - Reuters